In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A People-Driven Research Organization

Executive Summary

In the battle for the hearts and minds of young scientists, drug companies are losing out to biotech companies and discovery boutiques. Big pharma needs to attract top talent in much the same way small companies do--creating pathways to allow scientists to achieve their professional and personal aspirations, providing an unmatched research environment, and offering competitive incentives and rewards. Making such opportunities available may push pharma companies beyond their comfort zone, but not making them available will be even worse.

You may also be interested in...



EU UDI: Commission Explains Basics And Addresses Uncertainties In Q&A Document

Unique Device Identification (UDI) is key to better transparency and traceability in the EU. But UDI is new to medtech manufacturers and complex. The commission has published some helpful pointers.

Moderna Takes Middle Ground On Pricing With 100 Million Dose US Agreement

Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.

China-US Divide Deepens On Covid Vaccines, Azar Taiwan Visit

China has shown willingness to go tit-for-tat in its bilateral disputes with the US and the latest comments from US officials show an underlying distrust over clinical data and vaccines safety in China, raising fresh concerns just when collaboration is needed to accelerate availability of the first vaccines in the global pandemic.

Topics

Related Companies

UsernamePublicRestriction

Register

WI965023

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel